SRR13311180
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.570
- PROTEIN_SECRETION+0.510
- G2M_CHECKPOINT+0.450
- UNFOLDED_PROTEIN_RESPONSE+0.390
- FATTY_ACID_METABOLISM+0.380
- MTORC1_SIGNALING+0.350
- MYC_TARGETS_V1+0.350
- ANDROGEN_RESPONSE+0.340
- GLYCOLYSIS+0.330
- MITOTIC_SPINDLE+0.330
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.310
- ALLOGRAFT_REJECTION-0.290
- ANGIOGENESIS-0.230
- NOTCH_SIGNALING-0.200
- INTERFERON_GAMMA_RESPONSE-0.170
- IL6_JAK_STAT3_SIGNALING-0.160
- HEDGEHOG_SIGNALING-0.140
- WNT_BETA_CATENIN_SIGNALING-0.130
- PANCREAS_BETA_CELLS-0.120
- INFLAMMATORY_RESPONSE-0.110
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR12696742 | — | — | 0.840 |
| 2 | MNG1079 | — | — | 0.839 |
| 3 | TCGA-66-2783-01A-01R-1201-07 | — | cohortSQ2 | 0.821 |
| 4 | TCGA-18-4086-01A-01R-1100-07 | — | cohortSQ2 | 0.811 |
| 5 | TCGA-4Z-AA7Y-01A-11R-A39I-07 | — | — | 0.809 |
| 6 | TCGA-CF-A3MG-01A-11R-A20F-07 | — | — | 0.809 |
| 7 | MNG778 | — | — | 0.804 |
| 8 | GSM5359435 | — | — | 0.803 |
| 9 | SRR13311168 | — | — | 0.803 |
| 10 | R122 | — | — | 0.796 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 34 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.570 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.510 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.450 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.390 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.380 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.350 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.350 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.340 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.330 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.330 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.320 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.320 | Remibrutinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.290 | Remibrutinib | — uncovered |
| HYPOXIA | 0.280 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.270 | Temsirolimus | — uncovered |
| BILE_ACID_METABOLISM | 0.260 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.260 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.250 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.240 | Inavolisib | — uncovered |
| PEROXISOME | 0.240 | Idelalisib | — uncovered |